CN102895238B - Gypensapogenin A在抗细菌药物中的应用 - Google Patents
Gypensapogenin A在抗细菌药物中的应用 Download PDFInfo
- Publication number
- CN102895238B CN102895238B CN201210417262.9A CN201210417262A CN102895238B CN 102895238 B CN102895238 B CN 102895238B CN 201210417262 A CN201210417262 A CN 201210417262A CN 102895238 B CN102895238 B CN 102895238B
- Authority
- CN
- China
- Prior art keywords
- gypensapogenin
- antibacterial
- application
- preparation
- belongs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PYGRZYXAMLFMOS-IBMFSSKUSA-N gypensapogenin a Chemical compound O=C1C(=C(C)C)CC=C1[C@@H]1[C@@H](CC[C@H]2[C@]3(CCC4=C2[C@H]2CC[C@H](O2)C4(C)C)C)[C@@]3(C)CC1 PYGRZYXAMLFMOS-IBMFSSKUSA-N 0.000 title claims abstract description 56
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title abstract description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 5
- 241000588769 Proteus <enterobacteria> Species 0.000 claims abstract description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 4
- 229940124350 antibacterial drug Drugs 0.000 claims description 6
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 230000009707 neogenesis Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 201000007336 Cryptococcosis Diseases 0.000 abstract 1
- 241000221204 Cryptococcus neoformans Species 0.000 abstract 1
- 241000589540 Pseudomonas fluorescens Species 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及Gypensapogenin A在制备抗细菌药物中的应用，属于医药领域。Gypensapogenin A具有很强的抑制大肠杆菌、荧光假单孢菌、金黄色葡萄球、变形杆菌、新生隐球菌的作用，因此Gypensapogenin A可作为具有抗细菌的化合物，并有望在制备相关药物中得到应用。本发明涉及的Gypensapogenin A在制备抗细菌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于细菌抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于细菌感染的防治显然具有显著的进步。
Description
技术领域
本发明涉及Gypensapogenin A的用途，尤其涉及Gypensapogenin A在制备抗细菌药物中的应用。
背景技术
致病菌的扩散及其耐药性的增强严重威胁着人类的健康和生命，抗菌药物已作为常规用药广泛用于艾滋病、器官移植以及慢性消耗性疾病（如癌症、糖尿病、尿毒症等）的治疗，虽然目前临床上使用的抗菌药剂（如酮康唑、阿米卡星、庆大霉素、活力康唑、伊曲康唑、特比萘芬、二性霉素、氟康唑等）对皮肤及浅表部位感染的疗效较好，但这些抗菌药物的蓄积毒性较强，常常引起肝肾损伤、消化道刺激、头晕、过敏等，所以寻找作用机理独特的新型抗菌药物成为当今药物研发的热点之一。
本发明涉及的化合物Gypensapogenin A是一个2012年发表（Li, N.et al., 2012. Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum. European Journal of Medicinal Chemistry 50, 173–178.）的新骨架化合物，该化合物拥有全新的骨架类型，目前的用途仅仅涉及人肿瘤细胞株的细胞毒活性（Li, N. et al., 2012. Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum. European Journal of Medicinal Chemistry 50, 173–178.），对于本发明涉及的Gypensapogenin A在制备抗细菌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于细菌抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于细菌感染的防治显然具有显著的进步。
发明内容
本发明的目的在于：
提供一种本发明的Gypensapogenin A在制备抗细菌药物中的应用。
所述化合物Gypensapogenin A结构如式（Ⅰ）所示：
式（Ⅰ）
Gypensapogenin A具有很强的抑制大肠杆菌 、荧光假单孢菌、金黄色葡萄球 、变形杆菌、新生隐球菌的作用，所以GypensapogeninA可作为具有抗菌作用的化合物，并有望在制备抗菌药物中得到应用。
Gypensapogenin A在制备抗细菌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于细菌抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于细菌感染的防治显然具有显著的进步。
具体实施方式
本发明所涉及化合物Gypensapogenin A的制备方法参见文献（Li,N. et al., 2012. Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum. European Journal ofMedicinal Chemistry 50, 173–178.和Wei, J.X. et al.,1982. Two new dammaran sapogenins from leaves of Panax notoginseng. Planta Medica, 45(3): 167-171.）。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
实施例1：本发明所涉及化合物Gypensapogenin A片剂的制备：
取20克化合物Gypensapogenin A，加入制备片剂的常规辅料180克，混匀，常规压片机制成1000片。
实施例2：本发明所涉及化合物Gypensapogenin A胶囊剂的制备：
取20克化合物Gypensapogenin A，加入制备胶囊剂的常规辅料如淀粉180克，混匀，装胶囊制成1000片。
下面通过药效学实验来进一步说明其药物活性。
实验例：Gypensapogenin A抗菌活性
抗菌活性实验是采用浓度稀释的方法，每次测定重复三次，测试病原菌有大肠杆菌 、荧光假单孢菌、金黄色葡萄球 、变形杆菌、新生隐球菌，菌液浓度为105个/mL。Gypensapogenin A起始浓度为50.0μg/mL（5％二甲基亚砜DMSO），梯度稀释至0.098 μg/mL，等量体积的菌液和测试样品混合培养在96孔板中，细菌培养温度分别为37℃，培养时间24h后观察，若发现没有菌落形成时为样品最低抗菌浓度，即MIC值。该实验阳性对照为硫酸阿米卡星，Gypensapogenin A抗菌结果见表1。
表1 Gypensapogenin A抗菌MIC值（μg/mL）
结论： Gypensapogenin A具有很强的抗细菌活性，因此本发明的Gypensapogenin A有望被用于制备新型抗菌药物。
Claims (1)
1.Gypensapogenin A在制备抗细菌药物中的应用，其所述的细菌为大肠杆菌 、荧光假单孢菌、金黄色葡萄球 、变形杆菌和新生隐球菌，所述化合物Gypensapogenin A结构如式（Ⅰ）所示：
式（Ⅰ）。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417262.9A CN102895238B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin A在抗细菌药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417262.9A CN102895238B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin A在抗细菌药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102895238A CN102895238A (zh) | 2013-01-30 |
| CN102895238B true CN102895238B (zh) | 2014-04-16 |
Family
ID=47567924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210417262.9A Active CN102895238B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin A在抗细菌药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102895238B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103027907A (zh) * | 2012-11-19 | 2013-04-10 | 何晓涛 | Aphanamixoid A在制备抗细菌药物中的应用 |
-
2012
- 2012-10-26 CN CN201210417262.9A patent/CN102895238B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102895238A (zh) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895238B (zh) | Gypensapogenin A在抗细菌药物中的应用 | |
| CN102872030B (zh) | Gypensapogenin B在制备抗细菌药物中的应用 | |
| CN103251611A (zh) | Aspeverin在制备抗细菌药物中的应用 | |
| CN103462968B (zh) | Incarviatone A在制备抗细菌药物中的应用 | |
| CN102872059B (zh) | Gypensapogenin B在制备抗人体真菌药物中的应用 | |
| CN103446125B (zh) | Lycojaponicumin B在制备抗细菌药物中的应用 | |
| CN102872105B (zh) | Houttuynoid C在抗细菌药物中的应用 | |
| CN102861076B (zh) | Houttuynoid A在制备抗细菌药物中的应用 | |
| CN102872090B (zh) | Houttuynoid B在制备抗细菌药物中的应用 | |
| CN103446114A (zh) | Sarcaboside A在抗细菌药物中的应用 | |
| CN102861027B (zh) | Gypensapogenin A在抗人体真菌药物中的应用 | |
| CN103381153B (zh) | Chukrasone B在制备抗细菌药物中的应用 | |
| CN103381164B (zh) | Chukrasone A在制备抗细菌药物中的应用 | |
| CN103463037B (zh) | Lycojaponicumin A在制备抗细菌药物中的应用 | |
| CN103446115A (zh) | Sarcaboside A在抗人体真菌药物中的应用 | |
| CN103463075B (zh) | Lycojaponicumin C在制备抗细菌药物中的应用 | |
| CN103462989A (zh) | Sarcaboside B在抗人体真菌药物中的应用 | |
| CN103463029B (zh) | Lycojaponicumin B在制备抗人体真菌药物中的应用 | |
| CN103446135B (zh) | Lycojaponicumin A在制备抗人体真菌药物中的应用 | |
| CN102861083B (zh) | Houttuynoid B在抗人体真菌药物中的应用 | |
| CN103027907A (zh) | Aphanamixoid A在制备抗细菌药物中的应用 | |
| CN103372004B (zh) | Chukrasone B在制备抗人体真菌药物中的应用 | |
| CN102861087B (zh) | Houttuynoid D在抗人体真菌药物中的应用 | |
| CN103446106A (zh) | Sarcaboside B在抗细菌药物中的应用 | |
| CN102872146A (zh) | Houttuynoid D在抗细菌药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GU YONGLIANG Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141225 Address after: 226400, No. 6, Southeast River, dug Town, Rudong County, Jiangsu Patentee after: Gu Yongliang Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |